|
|
Profile
|
Delegates :
Shuichi Toriya |
|
Incorporated :
January 15 , 2015 |
Paid in Capital :
100 Million yen |
Employees :
12 人 |
Address :
Global Business Hub Tokyo, Otemachi Financial City Grand Cube 3F 9-2, Otemachi 1-chome, Chiyoda-ku, TOKYO
〒100-0004
|
TEL/FAX :
+81-3-4243-6081 / +81-3-4243-6097 |
URL：
http://www.renatherapeutics.com/index.html |
Attachment :
|
Mission/Background :
Rena Therapeutics is a Tokyo based DDS platform provider for Nucleic Acid Medicine.
Our technology, Hetero-Duplex Oligonucleotide Technology, is new generation platform of nucleic acid medicine, which realizes targeting delivery by its unique structure. |
|
Technology & Business
|
Hetero-Duplex Oligonucleotide (HDO) Technology can be applicable to your drug assets (your target genes, DDS ligands etc.) and maximize your assets business potential.
Advantages of HDO technology is as below:
- Delivery
Realize specific targeting by conjugated various delivery molecules to complimentary sense strand (lower strand, as illustrated above) without modification on antisense antisense strands
- Efficacy
Realize very high knockdown efficacy (over 20x knock-down effect compared to ASO)
- Applicability
HDO Technology can be applied to any ASO in development, target genes and delivery ligands in your drug assets.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Hetero-Duplex Olgonucleotide
|
Discovery
|
Platform technology for nucleic acid medicine drug discovery and development
|
Drug development alliance with pharmaceutical companies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Rena Therapeutics Inc. announced that it has executed a non-exclusive license agreement with Ionis Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Ltd..
|
|
Alliance strategy
|
We would like to form an alliance with a company that is interested in licensing intellectual property related to our nucleic acid drug discovery platform technology and joint research of nucleic acid drugs using our nucleic acid drug discovery platform technology.
|
|
|